Eli Lilly and Company is a global pharmaceutical company that discovers, develops, and markets a wide range of human pharmaceuticals. Its primary customers include healthcare providers, hospitals, and patients. Revenue is generated from the sale of various medications, with significant products including insulin products (approximately 30%), oncology drugs like Alimta and Cyramza (around 25%), diabetes treatments such as Trulicity (about 20%), and other therapeutic areas including mental health and autoimmune disorders (approximately 25%). Factors supporting the company's endurance include a strong pipeline of new drugs and established products, while challenges may arise from patent expirations and competition from generic drugs.
—
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, and markets a wide range of human pharmaceuticals. Its primary customers include healthcare providers, hospitals, and patients. Revenue is generated from the sale of various medications, with significant products including insulin products (approximately 30%), oncology drugs like Alimta and Cyramza (around 25%), diabetes treatments such as Trulicity (about 20%), and other therapeutic areas including mental health and autoimmune disorders (approximately 25%). Factors supporting the company's endurance include a strong pipeline of new drugs and established products, while challenges may arise from patent expirations and competition from generic drugs.
—
Daily adjusted close
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, and markets a wide range of human pharmaceuticals. Its primary customers include healthcare providers, hospitals, and patients. Revenue is generated from the sale of various medications, with significant products including insulin products (approximately 30%), oncology drugs like Alimta and Cyramza (around 25%), diabetes treatments such as Trulicity (about 20%), and other therapeutic areas including mental health and autoimmune disorders (approximately 25%). Factors supporting the company's endurance include a strong pipeline of new drugs and established products, while challenges may arise from patent expirations and competition from generic drugs.